

DAFTAR PUSTAKA

- Akin F, Ayca B, Kose N, Duran M, Sari M, Uysal OK, *et al.*, 2012, "Serum Vitamin D levels Are Independently Associated With Severity of Coronary Artery Disease", In *Journal of Investigate Medicine*, vol 60:869-73.
- Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, *et al.*, 2005, "Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome", *Clinical Chemistry*, pp. 810-24.
- Baktir AO, Dogan Y, Sarh B, Sahin O, D Erkan D, Akpek M, *et al.*, 2016, "Relationship between serum 25-hydroxyvitamin D of Cardiology levels and The Syntax Score In Patients With Acute Coronary Syndrome, In Turkish Society of Cardiology National Congress, pp 293- 297.
- Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C, 2001. "Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels". *Am J Cardiol.*; 88: 265-69.
- Barbagelata NA, Granger CB, Oqueli E, 2007, "TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled Analysis". *Am Heart J*;133:273-282.
- Barter PJ, Ballantyne CM, Carmena R, *et al.* Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirtyperson/ten-country panel. *J Intern Med.* 2006;259(3):247-258.
- Bergmark, C., Dewan, A. and Orsoni, A., Merki, E., Miller, E.R., *et al.*, 2008 A Novel Function of Lipoprotein [a] as a Preferential Carrier of Oxidized Phospholipids in Human Plasma. *Journal of Lipid Research*, 49, 2230-2239.
- Chiodini BD, Barlera S, Franzosi MG, Beceiro VL, Inrona M, Tognoni G. 2003. APO B gene polymorphisms and coronary artery disease: a meta-analysis. *Atherosclerosis*;167:355-66.
- Cleeman JI. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *Journal of American Medical Association.* 2001;285(19):2486-97.
- Cynthia L, Bethea, Arubala P, Reddy, Matthew, Flowers *et al.*, 2015. High Fat Diet Decreases Beneficial Effects of Estrogen on Serotonin-Related Gene Expression in Marmosets. *Prog Neuropsychopharmacol Biol Psychiatry.* April 3; 58: 71-80.
- Dahlan S, 2004, "Statistika Untuk Kedokteran dan Kesehatan", editor Susalit E, Wangge G, Setiawan H, Arkans, Jakarta.

- Delima, Mihardja L, Siswoyo H., 2009. "Prevalensi dan Faktor Determinan Penyakit Jantung di Indonesia", dalam: Buletin Penelitian Kesehatan. 37:142-159.
- Departemen Kesehatan RI. 2013. "Pharmaceutical Care untuk Pasien Penyakit Jantung Koroner": Fokus Sindrom Koroner Akut. Bina Farmasi Komunitas dan Klinik Ditjen Bina Kefarmasian dan Alat Kesehatan Dep.Kes RI. Jakarta. Direktorat.
- Department of Health Western Australia, 2009, "The Model of Care for Acute Coronary Syndromes in Western Australia", Department of Health Western Australia, Perth, pp. 10-2.
- Elabscience, 2017, "Apolipoprotein B (Apo B-100) ELISA Kit ", 7th ed.
- Firdaus I, 2012, "Strategi Farmako-Invasif pada STEMI Akut", *J Kardiologi Indones*, 33, pp. 266-71.
- Gianfagna F, Veronesi G, Guasti L, Chambless LE, Brambilla P, Corrao G *et al.*, 2014. "Do apolipoproteins improve coronary risk prediction in subjects with metabolic syndrome? Insights from the North Italian Brianza cohort study". Elsevier Ireland Ltd. *Atherosclerosis* 236. p: 175-81.
- Hamm CW, Heeschen C, Falk E, Fox KAA, 2009, "Acute Coronary Syndromes: Pathophysiology, Diagnosis and Risk Stratification" in *ESC Textbook of Cardiovascular Medicine*, 2nd ed, Ed. Serruys PW, Camm AJ, Luscher TF, OUP Oxford, London, pp. 333-59.
- Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, *et al*, 2011, "ASC Guidelines for The Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation", *European Heart Journal*, 32, pp. 2999-3054.
- Jomansyah M, 2013. Angiografi Koroner. In: CDK-207, Vol 40(8), p 626-628.
- Holtzmann MJ, Jungner I, Walldius G, Ivert T, Nordqvist T, Östergren J, Hammar N. 2012. Dyslipidemia is a Strong Predictor of Myocardial infarction in Subjects with Chronic Kidney Disease. *Ann Med* 2010; Early Online, 1–8. Published in *Annals of Medicine*; 44: 262–270.
- Kalim, H, 2001, Diagnostik dan Stratifikasi Risiko Dini Sindrom Koroner Akut.dalam *Penyakit Kardiovaskular dari Pediatrik sampai Geriatrik*. Editor Kaligis, R.W.M., Kalim, H., Yusak, M., Ratnaningsih, E., Soesanto, A.M.Jakarta: Balai Penerbit RS Jantung Harapan Kita, 227-228.
- Khadem, Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM, 2009, "Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study". *Circulation*; 110:2687-2693.
- Knudtson M, 2014, "Coronary Scoring System", In; A Historical perspective, pp1-33.
- Kumar S, Saxena P, 2016, "To evaluate the Role of Plasma Vitamin D Levels as a Prognostic Marker and Its Relation to in Hospital Complications In patients With Acute Coronary Syndrome", in: *International Journal of Advances in medicine*, Nov;3(4):976-81.
- Libby P, 2004, "Current Concepts of The Pathogenesis of The Acute Coronary

- Syndromes”, *Circulation*, 104, pp. 365-72.
- Lindstedt L, Bates H, Hedlof E, 2013, “All oxidized LDL test are not created equal in what they measure”. Available from www.oxidized-ldl.com.
- McPhee SJ, Hammer GD, 2010. “Atherosclerosis” In *Pathophysiology Of Disease: An Introduction To Clinical Medicine*. Sixth Edition. McGraw-Hill Companies, Inc. pp: 311-18.
- McQueen MJ, Hawken S, Wang X. 2008. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. *Lancet*. 372(9634):224-233.
- Mendis, Tammi A, Rönnemaa T, Miettinen TA 2010, “World Health Organization Definition of Myocardial Infarction: 2008–09 Revision”, in *Int. J. Epidemiol. Advance Access*, pp 1-8.
- Menys YC, Durrington P, 2006, Apolipoprotein AI and B as therapeutic targets. *Journal of Internal Medicine*, 259: 462-72.
- Miles B, 2003, “Review of Lipoprotein”. Macmillan; p:822-35.
- National Academy of Clinical Biochemistry, 2007, “Laboratory Medicine Practice Guidelines: Biomarkers of Acute Coronary Syndromes and Heart Failure”, American Association for Clinical Chemistry.
- Overbaugh KJ, 2009, “Acute Coronary Syndrome”, *AJN*, 109(5), pp. 42-8.
- Penalva RA, Huoya M, Correia LC, Feitosa GS, Ladeia AM, 2008. Lipid Profile and Severity of Atherosclerotic Disease in Acute Coronary Syndrome. *Arq bras cardiol*, Vol.90(1), p 24-29.
- PERKI, 2015. Pedoman Tatalaksana Sindrom Koroner Akut. Perhimpunan Dokter Spesialis kardiovaskular Indonesia, Edisi 3.
- Pincus MR, Lifshitz MS, Bock JL. 2017. Analysis: Principles of Instrumentation In *Henry’s Clinical Diagnosis and Management By Laboratory Methodes*. 23th Edition. Elsevier. p: 33-59.
- Poon K & Walker D, 2011. Indication for Coronary Angiography Advances. In: *Diagnosis of Coronary Atherosclerosis*, Intech, pp 33-68.
- Pradeep, Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L, 2015, “Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease In The EPIC-Norfolk Prospective Population Study”. In: *Eur Heart J*; 28(22).
- Ramrakha, P, Hill, J, 2006, *Oxford Handbook of Cardiology: Coronary Artery Disease*. 1st ed. USA: Oxford University Press.
- [Roffi](#), [Patrono C](#), [Collet JP](#), [Mueller C](#), [Valgimigli M](#), [Andreotti F](#) et al., 2015. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *European Heart Journal*. Volume 37. Issue 3. pp: 267–315.
- Samsuria IK, Adninta I, 2015. Pemeriksaan Tingkat sdLDL Serum sebagai Petanda Diagnostik Stenosis Koroner. *IJCPdanML*, Vol 22(1), p 9-15
- Simes RJ, Topol EJ, Holmes DR Jr, 2005, “Link between the angiographic substudy and mortality outcomes in a large randomized trial of

- myocardial reperfusion". Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. *Circulation* ;91:1923–28.
- Sniderman AD, Furberg CD, Keech A, 2003. "Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment". *Lancet*; 361: 777–80.
- Stein EA, Sniderman A, Laskarzewski P. 2005. Assessment of reaching goal in patients with combined hyperlipidemias: low density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. *Am J Cardiol*; 96 (9 Suppl 1):36K– 43K.
- Serdar, Z., Aslan, K., Dirican, M., Sarandol, E., Yesilbursa, D. and Serdar, A. (2006) Lipid and Protein Oxidation and Antioxidant Status in Patients with Angiographically Proven Coronary Artery Disease. *Clinical Biochemistry*, 39, 794-803.
- Stocker R, Keaney, Jr, JF, 2004, "Role of Oxidative Modifications in Atherosclerosis", *Physiol Rev*, 84, pp.1381-478.
- Sullivan, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E, 2010, "High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study)": a prospective study. *Lancet*.;358:2026-2033.
- Thompson A, Danesh J. 2015. Association between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. *J Intern Med*;259:481–92.
- Toft-Petersen AP, Tilsted HH, Aaroe J, Rasmussen K, Christensen T, Griffin BA, et al. 2011. Small dense LDL particles - a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a casecontrol study. *Lipids Health Dis.*;10(1):21
- Vujovic A, Kotur-Stevuljevic J, Spasic S, Bujisic N, Martinovic J, Vuljovic M, Spasojevic-Kalimanovska V, Zeljkovic A, Pajic D. Evaluation of Different Formulas for LDL-C Calculation, *Lipids in Health and Disease*. 2010; 9(27):1-9.
- Walldius G, Jungner I, 2006, The Apo B/Apo A1 Ratio; A Strong new risk Factor for Cardiovascular Disease and A Target for Lipid Lowering Therapy- A Review of Evidence. *J Intern Med*;259: 493-519.
- Weinbrenner, T., Cladellas, M., Covas, MI., Fito, M., Tomas, M., Senti, M., Bruguera, J. and Marrugat, J. (2003) High Oxidative Stress in Patients with Stable Coronary Artery Disease. *Atherosclerosis*, 168, 99-106.
- WHO, 2003, 'World Data Table' in *The Atlas of Heart Disease and Stroke*, diunduh dari www.who.int/cardiovascular_disease/en/cvd_atlas
- Zahara F, Syafri M, Yerizel E, 2013. Gambaran Profil Lipid Pada Pasien Sindrom Koroner Akut di Rumah Sakit Khusus Jantung Sumatera Barat Tahun 2011-2012. *JKA*, 3(2); 167-72.
- Zambon A, Brown BG, Deeb SS, Brunzell JD, 2006. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. *J Intern Med*; 259: 473-480.